Preoperative chemotherapy with weekly docetaxel plus low-dose cisplatin and 5-fluorouracil for stage II/III squamous cell carcinoma of the esophagus

Esophagus

Volumn 7, Issue 2, 2010, Pages 95-100

  Yoshida, Takahiro ^a   Seike, Junichi ^a   Miyoshi, Takanori ^a,b   Yamai, Hiromichi ^a   Takechi, Hirokazu ^a   Yuasa, Yasuhiro ^a   Furukita, Yoshihito ^a   Yamamoto, Yota ^a   Umemoto, Atsushi ^a,c   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c Higashi Omiya General Hospital   (Japan)

Author keywords

Docetaxel; Esophageal cancer; Preoperative chemotherapy; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CHRONIC DIARRHEA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; EDEMA; ENDOSCOPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGOGRAPHY; ESOPHAGUS RESECTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; LYMPHADENECTOMY; MALE; MORBIDITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PREMEDICATION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THORACOSCOPY; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION;

EID: 77954768652     PISSN: 16129059     EISSN: 16129067     Source Type: Journal    
DOI: 10.1007/s10388-010-0234-8     Document Type: Article

References (26)

1. Akiyama H, Tsurumaru M, Udagawa H, Kajiyama Y. Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 1994;220:364-73. (Pubitemid 24313229)
2. Altorki N. En bloc esophagectomy: the three-field dissection. Surg Clin N Am 2005;85:611-9.
3. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, et al. A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). ASCO GI 2008 Abstract 4510.
4. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer: EORTC 24971/TAX 323 Study Group. N Engl J Med 2007;357:1695-704.
5. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991-7.
6. TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss; 2002.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16. (Pubitemid 30099779)
8. The Japan Esophageal Society. Guidelines for the clinical and pathologic studies on carcinoma of the esophagus. 10th edition. Tokyo: Kanehara; 2008.
9. Ide H, Ozawa S, Matsubara, Saito T, Shinoda M, Tachimori Y, et al. Comprehensive registry of esophageal cancer in Japan. Esophagus 2009;6:27-47.
10. Sekiguchi H, Akiyama S, Fujiwara M, Nakamura H, Kondo K, Kasai Y, et al. Phase II trial of 5-fluorouracil and low-dose cisplatin in patients with squamous cell carcinoma of the esophagus. Surg Today 1999;29:97-101.
11. Enzinger PC, Ilson DH, Kelsen DP. Chemotherapy in esophageal cancer. Semin Oncol 1999;26:12-20.
12. Hayashi K, Ando N, Watanabe H, Ide H, Nagai K, Aoyama N, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol 2001;31:419-23.
13. Iizuka T, Kakegawa T, Ide H, Ando N, Watanabe H, Tanaka O, et al. Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. Jpn J Clin Oncol 1992;22:172-6.
14. Fujiwara Y, Kamikonya N, Inoue T, Koishi K, Yoshikawa R, Nakao K, et al. Chemoradiotherapy for T3 and T4 squamous cell carcinoma of the esophagus using low-dose FP and radiation: a preliminary report. Oncol Rep 2005;14:1177-82.
15. Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-76.
16. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7.
17. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal cancer. J Clin Oncol 2001;19:305-13.
18. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-8.
19. Fiorica F, Di Bona D, Schepis F, Licata A, Shahied L, Venturi A, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut 2004;53:925-30.
20. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003;185:538-43.
21. Hsu CH, Yeh KH, Lui LT, Lee YC, Bu CF, Wang HP, et al. Concurrent chemoradiotherapy for locally advanced esophageal cancer: a pilot study by using daily low-dose cisplatin and continuous infusion of 5-fluorouracil. Anticancer Res 1999;19:4463-7.
22. Sai H, Mitsumori M, Yamauchi C, Araki N, Okumura S, Nagata Y, et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 2004;9:149-53.
23. Okitsu H, Umemoto A, Honda J, Okitsu N, Seike J, Tanida N, et al. Induction of TP and DPD expression by docetaxel and doxifluridine (5'-DFUR) in gastric cancer. Nihon Rinshou Geka Gakkai Zasshi (J Jpn Surg Assoc) 2004;65:587-93.
24. Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004;15:955-9.
25. Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer (Phila) 2001;91:2165-74.
26. Tahara M, Ohtsu S, Hironaka S, Boku N, Ishikura S, Miyata Y, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005;35:316-23.